Antibody Conjugate Supply or Characterization

The contract involves the supply or quality control performance of optimized antibody-lectin conjugates intended for preclinical use. This includes conducting rigorous analytical testing such as high-performance liquid chromatography (HPLC) and mass spectrometry (mass spec) to ensure the conjugates meet specified criteria. Key quality parameters to be documented include purity, stability, and endotoxin levels, which are critical for the safety and efficacy of the antibody-lectin conjugates in preclinical studies. This subcontract is issued by the National Institutes of Health under the Department of Health and Human Services and is associated with NAICS code 325412. The place of performance is in Bethesda, with the solicitation posted on June 4, 2026, and a response deadline of June 13, 2026. The contract is focused on providing specialized scientific and technical services related to biopharmaceutical development, supporting preclinical research efforts within the agency.